FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308406721> ?p ?o ?g. }

• W4308406721 abstract "<h3>Background</h3> Immune-checkpoint inhibitors have become the standard therapy in many types of cancers. The combination of anti-PD-1 and anti-CTLA4 demonstrated better anti-tumor response, but toxicity is a concern. Cytokines including IL-2, IL-12, IL-15, IL-21 that target immune cells have been developed to enhance immune response against tumors. IL-12, a multifunctional and potency cytokine, regulates both innate and adaptive immunity. IL-12 is considered to: (1) promote the proliferation and survival of T cell; (2) upregulate the chemokine and adhesion molecule to facilitate lymphocyte trafficking; (3) and trigger the T cell:DC crosstalk in combination with aPD1 treatment which might could potently enhance antitumor immunity. Therefore, this study aims to explore the synergistic anti-tumor immune response of IL-12 and anti-PD-1. <h3>Methods</h3> Demonstrate the combination tumor growth inhibition effect in 11 (MBT-2, MC38, CT-26, B16F10, 4T1, RENCA, B16F10, Hepa1-6, EMT-6, LL/2, J558) syngeneic mice tumor bearing model. Dose dependent effect, dosing sequential effect, and immunophenotyping in tumor microenvironment (TME) is conducted in CT26 and MC38 tumor bearing model. Mixed lymphocyte reaction (MLR) assay of Keytruda and human recombinant IL-12 (rHu-IL12) combination is conducted for <i>in vitro</i> lymphocyte proliferation and activation assessment. <h3>Results</h3> MBT-2, MC38, EMT-6, Hepa 1-6, and J558 is moderate to high responding to mIL-12 monotherapy (TGI 30 ~ 90%); CT-26 and 4T1 is slight responding to mIL-12 monotherapy (TGI 10 ~ 20%); LL/2, RENCA and B16F10 is non-responding to mIL-12 monotherapy. Anti-PD-1 combine with mIL-12 has permissive effect in MC38 (TGI 70% vs. 70% vs. 95%) and J558 (TGI 10% vs. 30% vs. 30%); has synergetic effect in CT26 (TGI 20% vs. 25% vs. 60%); and indifference in B16F10 and 4T1. Immunohistochemical and flow cytometric analyses confirmed that CD8+ T cells accumulate at the tumor margin and infiltrate the tumor mass in response to the combination therapy, resulting in favorable effector and regulatory T-cell ratios (12.33% : 4.64% to 18.40% : 2.03%), M1/M2 ratios (0.07%:0.08% vs. 0.1%:0.01%). In the MLR assay, rHu-IL12 could enhance the T cell proliferation combined with Keytruda; the T cell activation biomarker (CD25, CD69, HLA-DR) is also induced higher in rHu-IL12 combination group. <h3>Conclusions</h3> Systemic mIL-12 administration could show the robust tumor growth inhibition effect under specific TME setting, and reshape the tumor microenvironment even at extremely low concentration (20~50ng/mice). It gives us a hint to re-think the clinical setting and combination strategy of rHu-IL12 with anti-PD-1." @default.
• W4308406721 created "2022-11-11" @default.
• W4308406721 creator A5024213586 @default.
• W4308406721 creator A5027553364 @default.
• W4308406721 creator A5037152942 @default.
• W4308406721 creator A5069720813 @default.
• W4308406721 date "2022-11-01" @default.
• W4308406721 modified "2023-09-25" @default.
• W4308406721 title "1102 A single spark can start a prairie fire – re-think the combination strategy and clinical setting of IL-12 with anti-PD-1" @default.
• W4308406721 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1102" @default.
• W4308406721 hasPublicationYear "2022" @default.
• W4308406721 type Work @default.
• W4308406721 citedByCount "0" @default.
• W4308406721 crossrefType "proceedings-article" @default.
• W4308406721 hasAuthorship W4308406721A5024213586 @default.
• W4308406721 hasAuthorship W4308406721A5027553364 @default.
• W4308406721 hasAuthorship W4308406721A5037152942 @default.
• W4308406721 hasAuthorship W4308406721A5069720813 @default.
• W4308406721 hasBestOaLocation W43084067211 @default.
• W4308406721 hasConcept C13373296 @default.
• W4308406721 hasConcept C193419808 @default.
• W4308406721 hasConcept C203014093 @default.
• W4308406721 hasConcept C2776107976 @default.
• W4308406721 hasConcept C2776999253 @default.
• W4308406721 hasConcept C2777701055 @default.
• W4308406721 hasConcept C502942594 @default.
• W4308406721 hasConcept C71924100 @default.
• W4308406721 hasConcept C8891405 @default.
• W4308406721 hasConcept C98274493 @default.
• W4308406721 hasConceptScore W4308406721C13373296 @default.
• W4308406721 hasConceptScore W4308406721C193419808 @default.
• W4308406721 hasConceptScore W4308406721C203014093 @default.
• W4308406721 hasConceptScore W4308406721C2776107976 @default.
• W4308406721 hasConceptScore W4308406721C2776999253 @default.
• W4308406721 hasConceptScore W4308406721C2777701055 @default.
• W4308406721 hasConceptScore W4308406721C502942594 @default.
• W4308406721 hasConceptScore W4308406721C71924100 @default.
• W4308406721 hasConceptScore W4308406721C8891405 @default.
• W4308406721 hasConceptScore W4308406721C98274493 @default.
• W4308406721 hasLocation W43084067211 @default.
• W4308406721 hasOpenAccess W4308406721 @default.
• W4308406721 hasPrimaryLocation W43084067211 @default.
• W4308406721 hasRelatedWork W1995188936 @default.
• W4308406721 hasRelatedWork W2014893045 @default.
• W4308406721 hasRelatedWork W2778781711 @default.
• W4308406721 hasRelatedWork W3025154575 @default.
• W4308406721 hasRelatedWork W3094844892 @default.
• W4308406721 hasRelatedWork W4286629873 @default.
• W4308406721 hasRelatedWork W4304979265 @default.
• W4308406721 hasRelatedWork W4318053857 @default.
• W4308406721 hasRelatedWork W4360868614 @default.
• W4308406721 hasRelatedWork W4362003594 @default.
• W4308406721 isParatext "false" @default.
• W4308406721 isRetracted "false" @default.
• W4308406721 workType "article" @default.